C
1.78
-0.02 (-1.11%)
| Penutupan Terdahulu | 1.80 |
| Buka | 1.80 |
| Jumlah Dagangan | 23,019 |
| Purata Dagangan (3B) | 609,531 |
| Modal Pasaran | 121,368,288 |
| Harga / Buku (P/B) | 0.730 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 14 Aug 2025 |
| EPS Cair (TTM) | -1.78 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.25% |
| Nisbah Semasa (MRQ) | 14.25 |
| Aliran Tunai Operasi (OCF TTM) | -29.18 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -16.14 M |
| Pulangan Atas Aset (ROA TTM) | -18.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -62.04% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Climb Bio, Inc. | Bercampur | - |
AISkor Stockmoo
0.8
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | 0.75 |
|
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 8.07% |
| % Dimiliki oleh Institusi | 85.01% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 9.00 (HC Wainwright & Co., 405.62%) | Beli |
| Median | 8.50 (377.53%) | |
| Rendah | 8.00 (BTIG, 349.44%) | Beli |
| Purata | 8.50 (377.53%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 1.98 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| BTIG | 16 Oct 2025 | 8.00 (349.44%) | Beli | 1.95 |
| 30 Sep 2025 | 8.00 (349.44%) | Beli | 2.01 | |
| HC Wainwright & Co. | 13 Oct 2025 | 9.00 (405.62%) | Beli | 2.00 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 25 Nov 2025 | Pengumuman | Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 06 Nov 2025 | Pengumuman | Climb Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates |
| 03 Nov 2025 | Pengumuman | Climb Bio to Present at Upcoming Investor Conferences |
| 21 Oct 2025 | Pengumuman | Climb Bio Names Adam Villa as SVP, Technical Operations and Ashley Jones as SVP, People & Workforce Strategy |
| 17 Oct 2025 | Pengumuman | Climb Bio to Present Data at American Society of Nephrology (ASN) Kidney Week 2025 |
| 01 Oct 2025 | Pengumuman | Climb Bio Appoints Susan Altschuller, Ph.D., MBA as Chief Financial Officer |
| 29 Sep 2025 | Pengumuman | Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |